drugset / Trial / NCT02819583
CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
Phase 1/2
Unknown
10 enrolled
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital · collabHefei Binhu Hospital · collabThe First People's Hospital of Hefei · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.
Timeline
- Start
- 2016-10
- Primary completion
- 2018-09
- Completion
- 2019-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PCAR-019 | Cell therapy | — | Other |